文献速递泌尿男性生殖肿瘤

镭-223再治疗去势抵抗性前列腺癌骨转移的I/II期研究

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
PubMed 文献 · Ann Oncol · 2017-01-01

这项前瞻性I/II期研究评估了44例去势抵抗性前列腺癌骨转移患者在接受初始6次镭-223注射后出现进展,再接受最多6次额外注射的安全性和疗效。主要终点为安全性,结果显示再治疗耐受良好,血液学毒性极小,影像学骨进展率低。中位随访2年后,28例(64%)患者死亡,中位总生存期为24.4个月。

要点

  • 44例患者中29例(66%)完成全部6次再治疗注射,再治疗耐受良好。
  • 无4-5级血液学治疗中出现的不良事件,仅1例(2%)出现影像学骨进展。
  • 中位影像学无进展生存期为9.9个月,中位总生存期为24.4个月。

核心结论

  • 在疾病进展后接受第二疗程6次镭-223注射耐受良好,血液学毒性极小,影像学骨进展率低。
  • 有利的安全性和对疾病进展的早期效应表明镭-223再治疗可行,值得在更大规模的前瞻性试验中进一步评估。

研究设计与样本

  • 前瞻性I/II期研究,纳入44例去势抵抗性前列腺癌骨转移患者,初始6次镭-223注射无治疗中骨进展,随后出现影像学或临床进展。
  • 允许研究者酌情联用其他药物,但排除化疗和开始新的阿比特龙或恩扎卢胺。
  • 主要终点为安全性;探索性终点包括至影像学骨进展时间、至总碱性磷酸酶和前列腺特异性抗原进展时间、影像学无进展生存期、总生存期、至首次症状性骨骼事件(SSE)时间、无SSE生存期和至疼痛进展时间。

主要发现

  • 44例患者中29例(66%)接受了全部6次再治疗注射;距初始镭-223治疗结束的中位时间为6个月。
  • 仅1例(2%)患者出现影像学骨进展;8例(18%)出现影像学软组织肿瘤进展(3例淋巴结和5例内脏转移)。
  • 至总碱性磷酸酶和前列腺特异性抗原进展的中位时间分别为未达到和2.2个月;中位影像学无进展生存期为9.9个月(最长随访12.8个月)。
  • 5例(11%)患者死亡,8例(18%)经历首次SSE;中位总生存期、至首次SSE时间和无SSE生存期均未达到;36例可评估患者(基线最严重疼痛评分≤7)中5例(14%)出现疼痛进展。

局限性

  • 原文自述为小型研究且随访有限(small study with limited follow-up)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase I/II study assessed re-treatment safety and efficacy of up to six additional radium-223 injections. PATIENTS AND METHODS: Patients had castration-resistant prostate cancer and bone metastases and six initial radium-223 injections with no on-treatment bone progression; all had subsequent radiologic or clinical progression. Concomitant agents were allowed at investigator discretion, excluding chemotherapy and initiation of new abiraterone or enzalutamide. The primary endpoint was safety; additional exploratory endpoints included time to radiographic bone progression, time to total alkaline phosphatase and prostate-specific antigen progression, radiographic progression-free survival, overall survival, time to first symptomatic skeletal event (SSE), SSE-free survival, and time to pain progression. RESULTS: Among 44 patients, 29 (66%) received all six re-treatment injections. Median time from end of initial radium-223 treatment was 6 months. Forty-one (93%) reported ≥1 treatment-emergent adverse event. No grade 4-5 hematologic treatment-emergent adverse events occurred. Only one (2%) patient had radiographic bone progression; eight (18%) had radiographic soft tissue tumor progression (three lymph node and five visceral metastases). Median times to total alkaline phosphatase and prostate-specific antigen progression were not reached and 2.2 months, respectively. Median radiographic progression-free survival was 9.9 months (12.8-month maximum follow-up). Five (11%) patients died and eight (18%) experienced first SSEs. Median overall survival, time to first SSE, and SSE-free survival were not reached. Five (14%) of 36 evaluable patients (baseline worst pain score ≤7) had pain progression. After 2 years of follow-up, 28 (64%) patients died, and the median overall survival was 24.4 months. CONCLUSIONS: Re-treatment with a second course of six radium-223 injections after disease progression is well tolerated, with minimal hematologic toxicity and low radiographic bone progression rates in this small study with limited follow-up. Favorable safety and early effects on disease progression indicate that radium-223 re-treatment is feasible and warrants further evaluation in larger prospective trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sartor O, Heinrich D, Mariados N, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol. 2017. PMID: 28961839. doi:10.1093/annonc/mdx331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。